Kala Pharmaceuticals, Inc.

KALA

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

None scheduled

Drug Pipeline

Drug Name	Phase	Indication	Designations
KPI-121 1% Ophthalmic Suspension dosed BID	Phase 3	Post Surgical Ocular Inflammation and Pain	-
Vehicle of KPI-121 0.25% Ophthalmic Suspension	Phase 3	Dry Eye Syndromes	-
KPI-121 Ophthalmic Suspension	Phase 3	Kerato Conjunctivitis Sicca	-
KPI-121 0.25% Ophthalmic Suspension	Phase 3	Dry Eye Syndromes	-
KPI-121 1.0%	Phase 3	Ocular Infections, Irritations and Inflammations	-
KPI-121	Phase 2	Dry Eye Syndromes	-
Vehicle	Phase 2	Blepharitis	-

Catalyst Timeline

0 upcoming, 0 past

No catalysts found.

Regulatory Approvals

KALA News